UY24930A1 - Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina) - Google Patents

Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina)

Info

Publication number
UY24930A1
UY24930A1 UY24930A UY24930A UY24930A1 UY 24930 A1 UY24930 A1 UY 24930A1 UY 24930 A UY24930 A UY 24930A UY 24930 A UY24930 A UY 24930A UY 24930 A1 UY24930 A1 UY 24930A1
Authority
UY
Uruguay
Prior art keywords
cis
amino
pharmaceutical compositions
oxatiolan
lamivudine
Prior art date
Application number
UY24930A
Other languages
English (en)
Inventor
Ngoc-Anh Thi Nguyen
Warren M Casey
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706295.4A external-priority patent/GB9706295D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY24930A1 publication Critical patent/UY24930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

La presente invención se refiere a composiciones farmacéuticas, novedosas que contienen (2R,cis)-4-amino-1-(2-hidroximetil-1,3-oxathiolan-5-il)-(1H)-pirimidin-2-ona ((-)-2`,3`-didesoxi,3`-thiacitidina, Epivir, lamivudina) y su uso en la terapia médica. LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS,NOVEDOSAS QUE CONTIENEN (2R,CIS)-4-AMINO-1-(2-HIDROXIMETIL-1,3-OXATIOLAN-5-IL)-(1H)-PI RIMIDIN-2-ONA((-)-2`,3`-DIDESOXI,3`-THIACITIDINA,EPIVIR,LAMIVUDINA) Y SU USO EN LA TERAPIA MEDICA.
UY24930A 1997-03-24 1998-03-23 Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina) UY24930A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4235397P 1997-03-24 1997-03-24
GBGB9706295.4A GB9706295D0 (en) 1997-03-26 1997-03-26 Lamivudine formulation

Publications (1)

Publication Number Publication Date
UY24930A1 true UY24930A1 (es) 2000-10-31

Family

ID=26311267

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24930A UY24930A1 (es) 1997-03-24 1998-03-23 Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina)

Country Status (40)

Country Link
US (1) US6004968A (es)
EP (1) EP0969815B1 (es)
JP (1) JP3264937B2 (es)
KR (1) KR100484695B1 (es)
CN (1) CN1191061C (es)
AP (1) AP1141A (es)
AR (1) AR011697A1 (es)
AT (1) ATE295150T1 (es)
AU (1) AU728461B2 (es)
BG (1) BG64690B1 (es)
BR (1) BR9808060B1 (es)
CA (1) CA2286126C (es)
CO (1) CO4980849A1 (es)
CY (1) CY2569B1 (es)
CZ (1) CZ298008B6 (es)
DE (1) DE69830154T2 (es)
EA (1) EA001990B1 (es)
EE (1) EE03996B1 (es)
ES (1) ES2239802T3 (es)
HK (1) HK1022853A1 (es)
HN (1) HN1998000045A (es)
HR (1) HRP980154B1 (es)
HU (1) HU225600B1 (es)
ID (1) ID29294A (es)
IL (1) IL131917A0 (es)
IS (1) IS2515B (es)
MY (1) MY116242A (es)
NO (1) NO326719B1 (es)
NZ (1) NZ337798A (es)
PA (1) PA8449301A1 (es)
PE (1) PE61699A1 (es)
PL (1) PL190505B1 (es)
PT (1) PT969815E (es)
RS (1) RS49772B (es)
SI (1) SI0969815T1 (es)
SK (1) SK283417B6 (es)
SV (1) SV1998000040A (es)
TW (1) TW536403B (es)
UY (1) UY24930A1 (es)
WO (1) WO1998042321A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6018044A (en) * 1998-01-02 2000-01-25 Roche Vitamins Inc. Light screening compositions
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
WO2004075913A1 (ja) * 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
US20040228804A1 (en) * 2003-05-16 2004-11-18 Jones Alonzo H. Nasal administration of xylitol to a non-human mammal
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
CN100427082C (zh) * 2005-08-02 2008-10-22 盛华（广州）医药科技有限公司 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
RU2587782C1 (ru) * 2015-01-19 2016-06-20 Общество с ограниченной ответственностью "Трейдсервис" Стабильная фармацевтическая композиция ламивудина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
TW536403B (en) 2003-06-11
ATE295150T1 (de) 2005-05-15
SI0969815T1 (es) 2005-08-31
BG103818A (en) 2000-06-30
AU728461B2 (en) 2001-01-11
JP2001501974A (ja) 2001-02-13
PT969815E (pt) 2005-07-29
ES2239802T3 (es) 2005-10-01
PL336038A1 (en) 2000-06-05
KR100484695B1 (ko) 2005-04-22
IL131917A0 (en) 2001-03-19
DE69830154T2 (de) 2005-10-13
CO4980849A1 (es) 2000-11-27
PA8449301A1 (es) 2000-05-24
JP3264937B2 (ja) 2002-03-11
SK283417B6 (sk) 2003-07-01
EA001990B1 (ru) 2001-10-22
EE03996B1 (et) 2003-04-15
NO326719B1 (no) 2009-02-02
CZ298008B6 (cs) 2007-05-23
AP1141A (en) 2003-01-29
KR20010005624A (ko) 2001-01-15
HUP0002982A3 (en) 2001-12-28
CA2286126A1 (en) 1998-10-01
SK129999A3 (en) 2000-07-11
AR011697A1 (es) 2000-08-30
IL131917A (en) 2001-01-11
PL190505B1 (pl) 2005-12-30
BR9808060B1 (pt) 2009-05-05
IS5184A (is) 1999-09-17
EP0969815A2 (en) 2000-01-12
EE9900440A (et) 2000-04-17
NO994619D0 (no) 1999-09-23
MY116242A (en) 2003-12-31
NZ337798A (en) 2001-03-30
AU7208498A (en) 1998-10-20
CY2569B1 (en) 2008-07-02
DE69830154D1 (de) 2005-06-16
HRP980154A2 (en) 1998-12-31
HN1998000045A (es) 1999-03-19
IS2515B (is) 2009-06-15
WO1998042321A2 (en) 1998-10-01
CN1255849A (zh) 2000-06-07
YU47799A (sh) 2002-06-19
EA199900757A1 (ru) 2000-08-28
BG64690B1 (bg) 2005-12-30
EP0969815B1 (en) 2005-05-11
WO1998042321A3 (en) 1999-01-07
ID29294A (id) 2001-08-16
RS49772B (sr) 2008-06-05
HK1022853A1 (en) 2000-08-25
HU225600B1 (en) 2007-05-02
HUP0002982A2 (hu) 2001-01-29
SV1998000040A (es) 1999-03-16
NO994619L (no) 1999-11-23
CZ340399A3 (cs) 2000-04-12
AP9901657A0 (en) 1999-09-30
PE61699A1 (es) 1999-07-08
BR9808060A (pt) 2000-03-08
US6004968A (en) 1999-12-21
CA2286126C (en) 2003-08-12
HRP980154B1 (en) 2002-06-30
CN1191061C (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
UY24930A1 (es) Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina)
ES2179193T3 (es) Combinaciones sinergicas de zidovudina, 1592u89 y 3tc.
DE60206137D1 (de) Kräuterpflanzen enthaltende artzneimittel
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
ATE293433T1 (de) Formulierungen mit antiviraler wirkung
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
GT200200247A (es) Formulaciones farmaceuticas de 5,7,14-triazatetra-ciclo[10.3.0 2,11.0 4,9]-hexadeca-2(11),3,5,7,9-pentaeno
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR0209440A (pt) Sulfonamidas
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
BR0114912A (pt) Kahalalide f
ES2163896T3 (es) Composiciones para aumentar la concentracion y/o motilidad de los espermatozoos en humanos.
CO4900074A1 (es) Combinaciones antivirales
BR9107135A (pt) Composicoes do tipo gel com melhor controle de oleos
ATE361059T1 (de) Antivirale zusammensetzungen
DE60331999D1 (de) Hautaufhellende zusammensetzung
ECSP982450A (es) Composiciones farmaceuticas
DE69413957D1 (de) Orale zusammensetzungen mit verbesserter stabilität, welche natrium-carbonat und bicarbonat-salz enthalten
DE60137952D1 (de) Pharmazeutische zusammensetzungen mit epinastin und pseudoephedrin
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR007616A1 (es) Combinaciones antivirales
ES2178960B1 (es) Utilizacion de fracciones de lanolina ricas en ceramidas para el tratamiento de la piel, y composiciones que las contienen.
BR0305664A (pt) Material à base do corante azuleno para utilização em terapia fotodinâmica
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180323